

**An artemisinin derivative for the Treatment of CMV Viral Infections. (Hadasit)****code:** 8-2010-21

Dana Wolf, Hadassah Ein Kerem, Clinical Microbiology and Infectious Diseases, Virology

**Need:**

Novel approach for the treatment of Cytomegalovirus (CMV) infection. The technology addresses unmet medical need in the field of CMV management. The use of currently available anti-CMV drugs is limited due to toxicity, low oral bioavailability and drug resistance.

**Innovation:**

We have a pre-clinical proof of concept demonstrating the utility of a small molecule as an anti-viral agent (NDA will be required to disclose the identity of our candidate compound). The compound was also proven to be safe and efficacious in a phase I-II clinical study conducted by a major biopharmaceutical company for another indication.

**Indications / Applications:**

Treatment and prevention of human cytomegalovirus infection. Prophylaxis & treatment in transplant patients. Treatment of symptomatic and asymptomatic congenital infection. Prevention of maternal-fetal transmission in pregnant woman. Treatment of symptomatic infection in healthy individuals.

**Competitive Advantages:**

Novel, orally administered, potent and safe, anti - HCMV drug for the prevention and treatment of HCMV infection.

**Contact for more information:**Tal Almog , 054-3187538

---

Hadasit Medical Research Services & Development Ltd  
Mother & Child Pavilion, Hadassah Ein Kerem, Jerusalem , 91120 Israel  
Phone: +972-2-6778757, Fax: +972-2-6437712, E-mail: skimhi@hadassah.org.il